These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3510318)

  • 1. Failure of immunotherapy for metastatic renal cell carcinoma.
    Fowler JE
    J Urol; 1986 Jan; 135(1):22-5. PubMed ID: 3510318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma.
    Kurth KH; Marquet R; Zwartendijk J; Warnaar SO
    Eur Urol; 1987; 13(1-2):103-9. PubMed ID: 3582439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice.
    Lavin PT; Maar R; Franklin M; Ross S; Martin J; Osband ME
    Transplant Proc; 1992 Dec; 24(6):3059-64. PubMed ID: 1466057
    [No Abstract]   [Full Text] [Related]  

  • 8. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
    Wang Z; Zhang Y; Liu Y; Wang L; Zhao L; Yang T; He C; Song Y; Gao Q
    J Immunother; 2014 Jan; 37(1):43-50. PubMed ID: 24316555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
    Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
    Kugler A; Stuhler G; Walden P; Zöller G; Zobywalski A; Brossart P; Trefzer U; Ullrich S; Müller CA; Becker V; Gross AJ; Hemmerlein B; Kanz L; Müller GA; Ringert RH
    Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
    Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
    J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
    Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
    J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasectomy plus immunotherapy compared with immunotherapy alone in metastatic renal cell carcinoma.
    Ku JH; Kwak C
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):164-5. PubMed ID: 17355116
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy for metastatic renal cell cancer: effect on the primary tumor.
    Haas GP; Redman BG; Rao VK; Dybal E; Pontes JE; Hillman GG
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):130-5. PubMed ID: 8318498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.